Limited airway resection and reconstruction for paediatric tracheobronchial inflammatory myofibroblastic tumour

Interact Cardiovasc Thorac Surg. 2022 Aug 3;35(3):ivac117. doi: 10.1093/icvts/ivac117.

Abstract

Objectives: The paediatric tracheobronchial inflammatory myofibroblastic tumour (IMT) is a rare disease. Whether limited surgical resection is a feasible surgical approach for these patients remains controversial. The objectives of this study were to report the long-term prognosis after limited surgical resections on paediatric tracheobronchial IMT and provide a surgical management strategy for this rare disease.

Methods: Paediatric tracheobronchial IMT patients who underwent limited surgical resection from 2012 to 2020 were enrolled in this study. The clinical characteristics, course of treatment and long-term outcomes of all participants were collated. We presented the accumulated data and analysed the feasibility of limited surgical resection on the paediatric tracheobronchial IMT.

Results: A total of 9 children with tracheobronchial IMTs were enrolled in our study. Cough and shortness of breath were the most common symptoms. All 9 participants underwent surgical treatment, including 2 tracheal reconstructions, 4 carinal reconstructions and 3 bronchial sleeve resections. Among the participants, 6/9 (66%) were positive for the anaplastic lymphoma receptor tyrosine kinase gene in terms of immunohistochemistry. None of the participants died of short-term complications. The follow-up period was 5.4 (range, 1.1-9.3) years, during which all participants remained well.

Conclusions: Limited surgical resection is preferred for paediatrics with tracheobronchial IMTs. Meanwhile, patients with complete resection have an excellent long-term prognosis.

Keywords: Paediatric; The long-term prognosis; Tracheobronchial inflammatory myofibroblastic tumour.

MeSH terms

  • Bronchi
  • Child
  • Granuloma, Plasma Cell*
  • Humans
  • Neoplasms*
  • Pediatrics*
  • Pneumonectomy
  • Rare Diseases